Anti-ZEBOV GP/Glycoprotein Reference Antibody (Maftivimab, RUO)

Catalog No.	VK623056
Brand	abinScience
Host species	Human
Species reactivity	Zaire ebolavirus (ZEBOV) (Zaire Ebola virus)
Form	Liquid
Storage buffer	0.01M PBS pH 7.4
Purity	>95% purity as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1, kappa
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target	Envelope glycoprotein, GP1, 2, GP, Shed GP, GP1, 2-delta, GP1, GP2, GP
References	1. Markham A. REGN-EB3: First Approval. Drugs. 2021 Jan;81(1):175-178. [VK623056] 2. Gaudinski MR, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. [VK623056]
Purification	Protein A/G purified from cell culture supernatant.
Biological activity	Maftivimab binds with high affinity to the recombinant histidine-tagged extracellular domain protein of Ebola virus Makona strain glycoprotein (K d = 2.97 × 10 nM [1]). Maftivimab potently neutralizes Ebola pseudovirus particles in vitro, with an IC 50 of 0.17 nM [1].
Endotoxin level	< 10 EU/mg
Expression system	Mammalian cells
Accession	Q05320
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative name	REGN-3470-3471-3479, REGN-3470/REGN-3471/REGN-3479, INMAZEB™(odesivimab-ebgn, maftivimab, andatoltivimab), 2135632-36-7
Note	For research use only. Not suitable for clinical or therapeutic use.